Produodopa 240 mg/ml + 12 mg/ml solution for infusion
*Company:
AbbVie LimitedStatus:
UpdatedLegal Category:
Product subject to medical prescription which may not be renewed (A)Active Ingredient(s):
*Additional information is available within the SPC or upon request to the company
Updated on 29 August 2025
File name
PIL_Produodopa_LU Site Addition_27Aug2025.pdf
Reasons for updating
- Change to section 6 - marketing authorisation holder
- Addition of manufacturer
Free text change information supplied by the pharmaceutical company
Addition of AbbVie Ludwigshafen as secondary packaging and QP release site to section 6 of the PIL. Removal of UK (NI) details from the Package Leaflet as part of the Windsor Framework Updates.
File name
Produodopa_PatientGuide_June 2023.pdf
Reasons for updating
- Add New Doc
Updated on 08 January 2024
File name
SmPC_Produodopa_V76_03Jan24.pdf
Reasons for updating
- New SPC for new product
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 08 January 2024
File name
PL_Produodopa_V76_03Jan24.pdf
Reasons for updating
- New PIL for new product
AbbVie Limited
Address:
Citywest Business Campus, Dublin 24, IrelandTelephone:
+353 1 428 7900Fax:
+353 1 428 7940